ID   WEE1_HUMAN              Reviewed;         646 AA.
AC   P30291;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   05-OCT-2010, entry version 118.
DE   RecName: Full=Wee1-like protein kinase;
DE            Short=WEE1hu;
DE            EC=2.7.10.2;
DE   AltName: Full=Wee1A kinase;
GN   Name=WEE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   MEDLINE=95262628; PubMed=7743995;
RA   Watanabe N., Broome M., Hunter T.;
RT   "Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell
RT   cycle.";
RL   EMBO J. 14:1878-1891(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=11528126;
RA   Cichutek A., Brueckmann T., Seipel B., Hauser H., Schlaubitz S.,
RA   Prawitt D., Hankeln T., Schmidt E.R., Winterpacht A., Zabel B.U.;
RT   "Comparative architectural aspects of regions of conserved synteny on
RT   human chromosome 11p15.3 and mouse chromosome 7 (including genes WEE1
RT   and LMO1).";
RL   Cytogenet. Cell Genet. 93:277-283(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-214.
RA   Igarashi M.;
RL   Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 215-646.
RX   MEDLINE=91351318; PubMed=1840647; DOI=10.1038/353080a0;
RA   Igarashi M., Nagata A., Jinno S., Suto K., Okayama H.;
RT   "Wee1(+)-like gene in human cells.";
RL   Nature 353:80-83(1991).
RN   [5]
RP   CHARACTERIZATION, AND MUTAGENESIS OF LYS-328.
RX   MEDLINE=93154348; PubMed=8428596;
RA   McGowan C.H., Russell P.;
RT   "Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2
RT   exclusively on Tyr15.";
RL   EMBO J. 12:75-85(1993).
RN   [6]
RP   PHOSPHORYLATION AT SER-642.
RC   TISSUE=Testis;
RX   PubMed=15150265; DOI=10.1074/jbc.M404728200;
RA   Lu R., Niida H., Nakanishi M.;
RT   "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint
RT   function.";
RL   J. Biol. Chem. 279:31164-31170(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127; SER-139 AND
RP   SER-165, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139 AND THR-173, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-67; SER-127; SER-139;
RP   SER-150; THR-173; THR-190 AND SER-312, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 291-575 IN COMPLEX WITH
RP   MAGNESIUM AND AN INHIBITOR.
RX   PubMed=15837193; DOI=10.1016/j.str.2004.12.017;
RA   Squire C.J., Dickson J.M., Ivanovic I., Baker E.N.;
RT   "Structure and inhibition of the human cell cycle checkpoint kinase,
RT   Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1
RT   regulation.";
RL   Structure 13:541-550(2005).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-210 AND ILE-472.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: May act as a negative regulator of entry into mitosis
CC       (G2 to M transition) by protecting the nucleus from
CC       cytoplasmically activated cyclin B1-complexed CDK1 before the
CC       onset of mitosis. Its activity increases during S and G2 phases
CC       and decreases at M phase when it is hyperphosphorylated. A
CC       correlated decrease in protein level occurs at M/G1 phase,
CC       probably due to its degradation. Specifically phosphorylates and
CC       inactivates cyclin B1-complexed CDK1 reaching a maximum during G2
CC       phase and a minimum as cells enter M phase. Phosphorylation of
CC       cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation
CC       of monomeric CDK1 does not occur.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Binds 2 magnesium ions per subunit.
CC   -!- ENZYME REGULATION: Synthesis is increased during S and G2 phases,
CC       presumably by an increase in transcription; activity is decreased
CC       by phosphorylation during m phase. Protein levels fall in M phase
CC       as a result of decreased synthesis combined with degradation.
CC       Activity seems to be negatively regulated by phosphorylation upon
CC       entry into mitosis, although N-terminal phosphorylation might also
CC       regulate the protein stability via protection from proteolysis or
CC       might regulate the subcellular location.
CC   -!- INTERACTION:
CC       Q9Y297:BTRC; NbExp=1; IntAct=EBI-914695, EBI-307461;
CC       Q9UKB1:FBXW11; NbExp=1; IntAct=EBI-914695, EBI-355189;
CC       P53350:PLK1; NbExp=1; IntAct=EBI-914695, EBI-476768;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- PTM: Phosphorylated during M and G1 phases. Also
CC       autophosphorylated.
CC   -!- PTM: Ubiquitinated and degraded at the onset of G2/M phase (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. WEE1 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U10564; AAB60401.1; -; mRNA.
DR   EMBL; AJ277546; CAC14173.1; -; Genomic_DNA.
DR   EMBL; X62048; CAA43979.1; -; mRNA.
DR   IPI; IPI00025830; -.
DR   PIR; S55048; S55048.
DR   RefSeq; NP_003381.1; -.
DR   UniGene; Hs.249441; -.
DR   PDB; 1X8B; X-ray; 1.81 A; A=291-575.
DR   PDB; 2IN6; X-ray; 1.90 A; A=291-575.
DR   PDB; 2IO6; X-ray; 2.20 A; A=291-575.
DR   PDB; 2Z2W; X-ray; 2.22 A; A=291-575.
DR   PDB; 3BI6; X-ray; 2.20 A; A=291-575.
DR   PDB; 3BIZ; X-ray; 2.20 A; A=291-575.
DR   PDB; 3CQE; X-ray; 2.50 A; A=291-575.
DR   PDB; 3CR0; X-ray; 2.30 A; A=291-575.
DR   PDBsum; 1X8B; -.
DR   PDBsum; 2IN6; -.
DR   PDBsum; 2IO6; -.
DR   PDBsum; 2Z2W; -.
DR   PDBsum; 3BI6; -.
DR   PDBsum; 3BIZ; -.
DR   PDBsum; 3CQE; -.
DR   PDBsum; 3CR0; -.
DR   ProteinModelPortal; P30291; -.
DR   SMR; P30291; 299-602.
DR   IntAct; P30291; 19.
DR   MINT; MINT-129561; -.
DR   STRING; P30291; -.
DR   PhosphoSite; P30291; -.
DR   PRIDE; P30291; -.
DR   Ensembl; ENST00000450114; ENSP00000402084; ENSG00000166483.
DR   GeneID; 7465; -.
DR   UCSC; uc001mhs.1; human.
DR   CTD; 7465; -.
DR   GeneCards; GC11P009550; -.
DR   H-InvDB; HIX0026153; -.
DR   HGNC; HGNC:12761; WEE1.
DR   HPA; CAB004619; -.
DR   MIM; 193525; gene.
DR   PharmGKB; PA366; -.
DR   eggNOG; prNOG19905; -.
DR   HOGENOM; HBG713564; -.
DR   HOVERGEN; HBG005050; -.
DR   InParanoid; P30291; -.
DR   OMA; RTYWNDS; -.
DR   OrthoDB; EOG9BZQN2; -.
DR   PhylomeDB; P30291; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Reactome; REACT_152; Cell Cycle, Mitotic.
DR   Reactome; REACT_1538; Cell Cycle Checkpoints.
DR   NextBio; 29236; -.
DR   PMAP-CutDB; P30291; -.
DR   ArrayExpress; P30291; -.
DR   Bgee; P30291; -.
DR   CleanEx; HS_WEE1; -.
DR   Genevestigator; P30291; -.
DR   GermOnline; ENSG00000166483; Homo sapiens.
DR   GO; GO:0005654; C:nucleoplasm; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007067; P:mitosis; IEA:UniProtKB-KW.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR017164; Wee1-like_protein_kinase.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037281; Wee1-like_protein_kinase; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division;
KW   Complete proteome; Kinase; Magnesium; Metal-binding; Mitosis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN         1    646       Wee1-like protein kinase.
FT                                /FTId=PRO_0000086810.
FT   DOMAIN      299    569       Protein kinase.
FT   NP_BIND     305    313       ATP (By similarity).
FT   COMPBIAS      9     12       Poly-Pro.
FT   COMPBIAS     34     43       Poly-Glu.
FT   ACT_SITE    426    426       Proton acceptor (By similarity).
FT   METAL       431    431       Magnesium; via carbonyl oxygen.
FT   METAL       463    463       Magnesium; via carbonyl oxygen.
FT   BINDING     328    328       ATP (By similarity).
FT   MOD_RES      67     67       Phosphoserine.
FT   MOD_RES     123    123       Phosphoserine; by CDK1 (Potential).
FT   MOD_RES     127    127       Phosphoserine.
FT   MOD_RES     139    139       Phosphoserine.
FT   MOD_RES     150    150       Phosphoserine.
FT   MOD_RES     165    165       Phosphoserine.
FT   MOD_RES     173    173       Phosphothreonine.
FT   MOD_RES     190    190       Phosphothreonine.
FT   MOD_RES     312    312       Phosphoserine.
FT   MOD_RES     642    642       Phosphoserine; by BRSK1; in vitro.
FT   VARIANT     210    210       G -> C (in dbSNP:rs34412975).
FT                                /FTId=VAR_041302.
FT   VARIANT     472    472       S -> I (in dbSNP:rs56411856).
FT                                /FTId=VAR_041303.
FT   MUTAGEN     328    328       K->R: Abolishes activity.
FT   CONFLICT     65     65       A -> E (in Ref. 3; CAA43979).
FT   HELIX       294    298
FT   STRAND      299    308
FT   STRAND      311    318
FT   TURN        319    321
FT   STRAND      324    331
FT   HELIX       338    352
FT   STRAND      362    368
FT   STRAND      371    377
FT   HELIX       384    394
FT   HELIX       400    419
FT   HELIX       429    431
FT   STRAND      432    435
FT   STRAND      458    461
FT   HELIX       480    482
FT   HELIX       485    488
FT   HELIX       495    510
FT   STRAND      518    520
FT   HELIX       521    527
FT   HELIX       540    549
FT   HELIX       554    556
FT   HELIX       560    564
SQ   SEQUENCE   646 AA;  71597 MW;  DB00623D304562A0 CRC64;
     MSFLSRQQPP PPRRAGAACT LRQKLIFSPC SDCEEEEEEE EEEGSGHSTG EDSAFQEPDS
     PLPPARSPTE PGPERRRSPG PAPGSPGELE EDLLLPGACP GADEAGGGAE GDSWEEEGFG
     SSSPVKSPAA PYFLGSSFSP VRCGGPGDAS PRGCGARRAG EGRRSPRPDH PGTPPHKTFR
     KLRLFDTPHT PKSLLSKARG IDSSSVKLRG SSLFMDTEKS GKREFDVRQT PQVNINPFTP
     DSLLLHSSGQ CRRRKRTYWN DSCGEDMEAS DYELEDETRP AKRITITESN MKSRYTTEFH
     ELEKIGSGEF GSVFKCVKRL DGCIYAIKRS KKPLAGSVDE QNALREVYAH AVLGQHSHVV
     RYFSAWAEDD HMLIQNEYCN GGSLADAISE NYRIMSYFKE AELKDLLLQV GRGLRYIHSM
     SLVHMDIKPS NIFISRTSIP NAASEEGDED DWASNKVMFK IGDLGHVTRI SSPQVEEGDS
     RFLANEVLQE NYTHLPKADI FALALTVVCA AGAEPLPRNG DQWHEIRQGR LPRIPQVLSQ
     EFTELLKVMI HPDPERRPSA MALVKHSVLL SASRKSAEQL RIELNAEKFK NSLLQKELKK
     AQMAKAAAEE RALFTDRMAT RSTTQSNRTS RLIGKKMNRS VSLTIY
//
